f5 Therapeutics Incorporated
Gary Choy is a seasoned professional in the biotechnology and pharmaceutical industries, currently serving as Co-Founder, Chairman, and CEO of f5 Therapeutics Incorporated since April 2020, focusing on targeted protein degradation for drug discovery. In addition, Gary Choy is the Founder, CEO, and Principal Consultant at T & G Consulting LLC, which aids emerging biotech companies in exploring commercial potentials. Previous roles include Vice President of Marketing at Samumed LLC and Global Marketing Leader for Rheumatology at The Janssen Pharmaceutical Companies of Johnson & Johnson, where responsibilities encompassed strategic market development and product launches. Gary Choy's extensive experience also includes leadership positions in sales and marketing at Idenix Pharmaceuticals, Roche, Abbott, and Pfizer. Academic qualifications include a BS in Marketing and Biology from Rutgers Business School and an MBA in Marketing from Rutgers University - Newark.
This person is not in any teams
f5 Therapeutics Incorporated
We are evolving targeted protein degradation to transform the landscape of drug discovery by utilizing the cell’s normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering impactful medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. Through our novel "function-first" approach, our goal is to expand the scope of degradable targets that cause human disease. Our lead oncology monotherapy compound, FFT-012, degrades an undruggable transcription factor at the end of the Wnt pathway which provides multiple applications in solid tumors. In addition to the Wnt and additional portfolio programs, we are engaging our oncology assets towards combinations with antibodies to provide novel Degrader Antibody Conjugates (DACs). By replacing the cytotoxic payloads of an Antibody Drug Conjugate (ADC), f5 Therapeutics is attempting to widen the therapeutic index of this modality.